Background: In vitro and animal studies suggested that soy protein and isoflavones promote weight and body fat loss. However, clinical trials in humans were few and the effects remained uncertain. Objectives: To examine whether soy protein with isoflavones and isoflavone extracts exert beneficial effects on body composition among postmenopausal women. Design: A double-blind randomized placebo-controlled trial was conducted among 180 postmenopausal Chinese women with mild hyperglycemia. After a 2-week adaptation, participants were randomly assigned to one of the three arms to receive 15 g soy protein and 100 mg isoflavones (Soy group), or 15 g milk protein and 100 mg isoflavones (Iso group), or 15 g milk protein (placebo group) on a daily basis for 6 months. Results: We observed a mild but significant favorable effect of soy protein with isoflavones on the changes of body weight (BW), body mass index, and body fat percentage relative to isoflavone extracts and milk protein after 6-month supplementation. The mean differences of BW between the Soy and the Iso groups were À0.75 kg (95% CI: À1.363 to À0.136, P ¼ 0.017), and between the Soy and the placebo groups were À0.60 kg (95% CI: À1.209 to À0.019, P ¼ 0.047). The mean difference of change percentage in body fat percentage between the Soy and the Iso groups was À3.74% (95% CI: À6.88 to À0.60%, P ¼ 0.02), and between the Soy and the placebo groups was À2.54% (95% CI: À5.69 to 0.12%. P ¼ 0.08). Conclusions: Six-month supplementation of soy protein with isoflavones had a mild favorable effect on body composition in postmenopausal women.
Introduction
Aging and menopause-induced estrogen deficiency is related to several changes that contribute to an increased risk of cardiovascular disease. These include an increase in body weight (BW) and fat mass (FM) and changes in fat metabolism.
1,2 Studies on postmenopausal hormone therapy (HT) have indicated the beneficial effects on body composition, such as preventing the menopausal-related abdominal fat increase, with preservation of muscle strength. 3, 4 As HT is associated with some adverse health effects, 5, 6 there is increasing interest to find an alternative to HT to prevent and delay the menopause-related health risks. Soy is a traditional Asian diet. Soybean contains many beneficial components, among which soy protein and isoflavones have received most research attention. Current evidence from in vitro and animal studies suggest that soy protein and isoflavones may promote weight loss and prevent body fat gain, with additional benefits over other protein sources. [7] [8] [9] Epidemiologic observations also indicated that persons with high soy food consumption have lower BWs than those with low soy intakes. 10, 11 A crosssectional study in western postmenopausal women 10 suggested a significant inverse relation between isoflavone consumption and BW, body mass index (BMI), waist circumference (WC), and total body FM (assessed by bioelectric impedance analysis). However, thus far, there have been only limited human trials investigating the long-term effects of dietary soy protein on body composition and weight loss. Although some randomized clinical trials (RCTs) suggested a beneficial effect of soy consumption on body composition, [12] [13] [14] inconsistent findings have been noted in other studies. 15, 16 The discrepancies among studies may be attributed to the variations in population characteristics, types of soy products, treatment duration, or inadequate sample size and random errors. As most studies were designed to compare the effects of soy protein with or without isoflavones, 12, 15, 16 the independent effects of isoflavones and its combined effect with soy protein were not delineated within the same study. Thus, the hypothesis of a beneficial effect of soy intake on body composition is still speculative. This paper reports the effects of soy protein with isoflavones and isoflavone extracts on changes in body composition among postmenopausal Chinese women with early untreated hyperglycemia. We hypothesized that the effect from soy protein together with isoflavones was more pronounced than isoflavone extracts alone.
Patients and methods

Participant recruitment
Potential participants were recruited from the local community through multiple strategies, including advertisements in local newspapers, health talk, written invitations, flyers, or subjects referrals. A total of 180 postmenopausal women with prediabetes or early diabetes were recruited to participate in a 6-month RCT. Subjects were Hong Kong Chinese menopausal women aged 48-70 years without a menstrual cycle for at least 1 year. Potential participants were excluded if they had a history of breast, uterine, or ovarian cancer, or stroke, coronary heart disease, or thyroid disease in the previous 5 years. They were also excluded if they currently, or in preceding 3 months, were on medication treatment for weight, glucose, lipids reduction, HT, or had a known allergy to soy or milk. The Ethical Committee of the Chinese university of Hong Kong approved the study and all the participants gave written informed consent before their enrollment.
Study design and intervention regimes
The study was a 6-month double-blind randomized placebocontrolled trial. Before formal admission to the study, subjects received 2 weeks of placebo, 15 g milk protein (Pacific Dairy Ingredients Co., Ltd, Shanghai), as run-in to get familiarized with the study requirement and procedure. Subjects with good compliance and without any side effects were randomly assigned to one of the three groups:
Soy protein (Solpro 931) and isoflavones (Solgen 40/s) were provided by Solbar Industries Ltd, Ashdod, Israel. Baseline measurements were performed before randomization. The intake compliance was assessed by counting the empty and remaining sachets at each face-to-face interview and estimating the percentage of supplements provided that had been consumed.
Randomization and blinding
Block randomization in block intervals of 15 was used for subject randomization. A list of random numbers was computer generated. Investigators not involved in subject contact, data collection, and analysis performed the randomization and the labeling work. The research staff assigned the number series to the subject in the order of their enrollment into the trial. Participants, investigators, and laboratory technicians were blinded to the treatment assignment until the conclusion of the trial. To assess the efficacy of blinding, the participants were asked, at the end of the intervention, to which group they thought they had been assigned. The proportion of the participants thought they were assigned to either one of the treatments was similar among the three treatment groups, indicating a successful blinding efficacy (data not shown).
Supplements preparation and delivery
The three kinds of preparation were formulated into isocaloric powder with similar color, taste, and odor as well as similar nutrients profile (protein, fat, carbohydrate, magnesium, calcium, sodium, etc.) by the addition of vitamins, minerals, and other additives. The daily dose was filled into identical looking unmarked packet. Each sachet contained 25 g powdered supplements, of which 60% was protein. A measure of 100 mg isoflavones, expressed in aglycone form, contained 35 mg daidzin, 59 mg genistin, and 4 mg glycitin, with 98.5% in conjugated form. Supplements were suggested to be mixed with 300 ml of water or any other liquid of subject's choice and detailed instruction on how to prepare the supplements was given by oral and video demonstration. To avoid taste fatigue, recipes were provided on how to include the supplement into usual diet. Subjects were asked to consume one packet daily, preferably at breakfast. Supplements were delivered to subjects at intervals of 1, 2, and 3 months after randomization. 
Power of study
With a planned number of subjects of 60 in each arm (180 subjects in total), we would have 80% power to find an improvement of 1.3% in the change of BW, and 3% in the change of body fat percentage (BF%), based on a conventional assumption of a level of 0.05 (for a two-sided t-test) and allowing for 10% withdrawal rate.
Data collection
Data were collected by trained interviewers through face-toface interview based on a structured and previously validated questionnaire on sociodemographic data, years since menopause (YSM), medical history, medication treatment, dietary habits, smoking, alcohol drinking, and physical activities.
Dietary intake and physical activity assessment During the course of intervention, dietary intake was measured by 3-day food records that were completed by subjects before each follow-up visit at 0, 3, and 6 months. Subjects received a 30-min training about utensil sizes, food amounts, and portion estimation. A set of visual aids including a food photo album and common household containers were also provided to help them estimate the amounts of the foods and beverage taken. Dietary nutrient intakes were calculated based on the China Food Composition Table (2004) . 17 Subjects were asked not to take supplements containing phytoestrogens or other extracts known to affect outcome measures. Participants' vitamin and mineral supplement use were recorded at the baseline visit and they were instructed to make no change in the doses during the study period. Participants were instructed to maintain their habitual diet and level of physical activity for the duration of the study.
Anthropometric measurements BW was measured to the nearest 0.1 kg, with the subjects in light clothing without shoes with the use of beam balance scale (Detecto, Clinicon Medical Ltd, Ontario, CA, USA). Height was measured in a standing position without shoes using a wall-mounted stadio-meter. BMI was calculated as weight in kilograms divided by height in meters squared. WC was measured at the level of midway between the lower rib margin and the iliac crest using a non-elastic tape without any pressure to the body surface. Hip circumference was measured at the level of the greater trochanters. WHR was calculated as the ratio of waist-to-hip circumferences. All measurements were performed twice and the average was recorded. BF%, FM, and free FM were determined by bioelectrical impedance analyzer (BIA, TBF-410-GS Tanita Body Composition Analyzer, Tokyo, Japan). The BF% was calculated from the impedance value as well as the pre-entered personal particulars, including weight, height, age, and sex through the built-in software. 18 These measurements were done after 10-12 h fasting. Subjects were requested to refrain from strenuous exercise 10-12 h before the measurements and empty their bladder before the measurements. The coefficients of variation for repeated measures were all o5% for BF%, FM, and free FM.
Statistical analysis
Statistical analysis was performed with the use of SPSS (version 13.0). All results were considered significant if the two-tailed P-value was o0.05. Baseline characteristics, dietary intake, and physical activity level were compared among the three study groups by analysis of variance (ANOVA). Data were analyzed according to an intentionto-treat principle including all 180 subjects. The last value carried forward was used for any missing data at follow-ups. Secondary analyses comprised a per protocol analysis, which included only 164 subjects with good compliance (defined as consuming X80% of provided supplements and done all assessments and sample collections). The non-compliant subjects were compared with the compliant subjects in baseline characteristics by w 2 or t-test.
A repeated-measures ANOVA was used to examine the interactive effects of treatment and time. The major approach to analysis was made by ANOVA and analysis of covariance (general linear model) to compare the percentage change at 3-and 6-month follow-ups among the three study groups. Percentage changes in outcome measures were calculated as ((follow-up valueÀbaseline value) Â 100%/baseline value). Least significant difference (LSD) test was used for post hoc multiple comparisons. We also conducted stratification analysis to examine whether the effect of soy supplementation differed by YSM and baseline BMI levels.
Results
From November 2007 to April 2008, a total of 180 eligible subjects who had successfully completed the 2-week run-in period were randomized into the three treatment arms ( Figure 1 ). Subjects who withdrew from the study were also invited for follow-up visits. In all, 176 subjects attended the mid-term visit and 175 attended the 6-month visit.
Dropout and compliance
In all, 18 women withdrew during the 2-week run-in because of loss of interests or time constraint, and 14 women (7.8%) withdrew during the study after randomization. The most important reasons for withdrawal after randomization were gastrointestinal tract discomfort (n ¼ 5), too busy to return for follow-up assessment (n ¼ 2), or developing some medical conditions (eye disease or heavy sore throat) (n ¼ 2). Detailed reasons for the withdrawal were indicated in Figure 1 . Relatively more dropouts were observed in the placebo Soy protein and body composition Z-m Liu et al group (n ¼ 9) than the Soy (n ¼ 3) and Iso (n ¼ 2) groups. Adherence was good and did not differ among the three groups. More than 90% of the subjects used 97% of the supplements.
Baseline characteristics
Baseline characteristics indicated that women in the three groups were comparable in terms of age, YSM, job status, education, family and medical history, smoking, dietary nutrient intake, and physical activity pattern (Table 1) . Women lost to follow-up (n ¼ 14) had similar baseline characteristics with women retained in the study (data not shown). Subjects' dietary intake and physical activity remained similar at baseline and at follow-ups (Table 1) .
Effects of soy on body composition
At baseline, the mean values of the anthropometric measures were similar among the three groups (Table 2 ). For the repeated-measures ANOVA, we found marginal significance in BW (P ¼ 0.097), BMI (P ¼ 0.101), and WHR (P ¼ 0.104) in the interaction terms between period and treatment. The mean BW at 6 months was significantly lower in the Soy group than the other two groups after adjusting for the potential confounders (YSM, baseline BW, baseline energy and soy protein intake, baseline physical activity level, P ¼ 0.042). A mild but significant decrease was found in BW change percentage from baseline to 6 months in the Soy group, as compared with the other two groups by either ANOVA (P ¼ 0.048) or analysis of covariance (P ¼ 0.019). Follow-up post hoc comparison indicated that the adjusted mean difference at 6 months between the Soy and the Iso groups was À0.75 kg (95% CI: À1.363 to À0.136, P ¼ 0.017), and between the Soy and the placebo groups was À0.60 kg (95% CI: À1.209 to À0.019, P ¼ 0.045). The adjusted mean difference in percentage change of BW at 6 months was À1.34% (95% CI: À2.344 to À0.333, P ¼ 0.009) between the Soy and the Iso groups, and À0.90% (95% CI: À1.911 to 0.011, P ¼ 0.052) between the Soy and the placebo groups.
Similar tendency was observed in BMI, WC, WHR, BF%, and FM, whereas statistical significance was found in BMI (P ¼ 0.048) and BF% (P ¼ 0.042) at 6-month percentage change after controlling for confounders. A marginal significance was observed at 3-month change percentage in BMI and BF%. For BF%, the adjusted mean difference in change percentage between the Soy and the Iso groups was À3.74% (95% CI: À6.88 to À0.60, P ¼ 0.02), and between the Soy and the placebo groups was À2.54% (95% CI: À5.69 to 0.12%. P ¼ 0.08). No significant difference between the Iso 18 give up or excluded during 2-week run-in Eligible subjects with pre or early DM: n =198 Further exploratory subgroup analysis using general linear model controlling for possible covariates revealed that soy protein together with isoflavones was more effective in lowering BW (P ¼ 0.023), BMI (P ¼ 0.025), WC (P ¼ 0.053), and body FM (P ¼ 0.053) in those within 4 years of their menopause (Table 3) .
Randomized: n=180
Dropouts: n=3 Reasons: Weight loss:1 Skin allergy:1 Menstrual recurrence:1 Dropouts: n=2 Reasons: Too busy:1 Develop disease: 1 Poor compliance: n=1 Dropouts: n=9 Reasons: GI discomfort:5 Too busy:1 Feel hot:1 Develop disease: 1 Taking glucose-lowering drug: 1 Poor compliance
Adverse events
We documented 75 reported adverse events, 25 in Soy group, 21 in Iso group, and 29 in placebo group. In all, 49.3% (n ¼ 35) complained of gastrointestinal discomfort, 25.3% (n ¼ 19) weight gain, and 14.7% (n ¼ 11) felt 'heatiness' (dry mouth, sore throat, acne, etc.). One person in the placebo group reported pain from swollen breast and three (two in Soy group, one in Iso group) suffered mild vaginal bleeding. The number and types of adverse events did not differ among the three groups.
Discussion
Our 6-month double-blind randomized placebo-controlled trial demonstrated that, relative to isoflavone extracts and milk protein, soy protein with isoflavones had a mild but significant effect on the improvement of BW and body composition in postmenopausal women, with responses being more pronounced among those within 4 years of their menopause. Po0.05 by comparing with Iso group by ANOVA. d Po0.05 by comparing with Iso group by ANCOVA. P(T Â G): P-value for interaction between time and group by repeated-measure ANOVA. *P-value by ANOVA analysis. **P-value by ANCOVA analysis after controlling for YSM, baseline body weight, baseline physical activity, baseline dietary energy, and soy protein intake and their interaction terms with treatment. The P-value for a,b,c,d are from LSD, post hoc multiple comparison tests. All the mean values and percentage changes presented in the table were unadjusted.
Soy protein and body composition Z-m Liu et al
Despite data from animal models generally supportive for the effects of soy protein or isoflavones on weight and fat loss when isocaloric diets are administered, 19 current information regarding similar effects in humans are limited with controversial results. Only three randomized placebocontrolled trials using soy protein with or without isoflavones as supplements examined the effects on body composition in peri-or postmenopausal women. One trial reported positive findings on body fat reduction, 12 whereas the other two did not. 15, 16 A study by Sites et al. 12 in 15 postmenopausal women reported that, compared with an isocaloric casein placebo, a 3-month daily shake supplement containing 20 g soy protein and 160 mg isoflavones prevented an increase in subcutaneous and total abdominal fat, whereas BW was unaffected. The study by Moeller et al. 16 among perimenopausal women showed that isoflavone-rich soy protein (40 g soy protein and 80.4 mg isoflavones) did not affect body mass, total body fat, and lean mass compared with whey protein or isoflavone-poor soy protein. A 12-month RCT 15 conducted among older postmenopausal women (60-75 years) reported that 25.6 g soy protein containing 99 mg isoflavones had no effect on BMI and WHR compared with milk protein. Differences in population characteristics, types of soy supplements, and methods for outcome measures may explain the inconsistent findings among studies. Women at different menopausal stage may respond differently to soy supplementation. Our subgroup analysis also suggested a more pronounced soy protein effect in early menopausal women (o4 YSM). Our finding of a nil effect of isoflavones supplementation without soy protein on anthropometric profile and body composition was consistent with an earlier finding, 20 but not with two others. 21, 22 It has been suggested that the purified isoflavones or isolated soy protein are not as effective as intact soy foods on the improvement of body composition and lipids profile. 13, 14, 23, 24 The favorable effect might be attributed to the presence of the other components in soy (such as soy fiber, saponin, polysaccharides, phytosterol, unsaturated fatty acid, etc.) and their interactions. 25 Compared with some notable positive findings, 12,14,26 our trial has observed a mild effect of soy on BW and BF% reduction, whereas this magnitude was comparable to the other two studies with the use of soy-based diet among overweight or obese patients. 13, 27 However, even this mild degree of effect may have important public health implications. Evidence has indicated that even a 1-kg increase in BW .05 by comparing with placebo group by ANCOVA. The P-value for a,b are from LSD, post hoc multiple comparison tests. *P-value by ANCOVA after controlling for baseline body weight, baseline physical activity, baseline dietary energy, and soy protein intake.
Soy protein and body composition Z-m Liu et al is associated with a 9% relative increase in diabetes prevalence in the general population. 28 For every 1% above a desirable BMI, the risk for CHD increases by 3.3% for women and by 3.6% for men. 29 Weight loss from pharmacotherapy is also generally modest ranging from 2.6 to 4.5 kg, or B2-3% of initial BW after even a longer treatment period (26-52 weeks) than ours. 30 Thus, it is not expected that soy, as a dietary supplement, will be as effective as the weight reduction agents in improving BW. However, the beneficial effects of soy, as part of diet, in weight control and body fat reduction would warrant further investigation. The mild effect of soy in our study could also possibly be ascribed to the use of only a moderate amount of soy protein in purified form, or the absence of restricted caloric intake during the study. Furthermore, our study participants consisted of women with prediabetes or early diabetes. Earlier studies indicated that physiologic abnormalities of diabetes may make weight loss more difficult and harder to maintain. 31 In addition, our participants had a mean BMI of 24.5 with 38% within the normal range. Thus, it is not surprising to observe a less remarkable improvement in body composition among the normal weight or mildly overweight subjects. However, our subgroup analysis by baseline BMI level did not show a more apparent effect in the higher BMI than the lower BMI group, although the findings from subgroup analysis should be treated with caution. Further studies are warranted to clarify whether the soy effect can be modified by baseline BMI status. As in many other studies, we used milk protein to serve as the placebo group. However, milk peptides may have active biological properties relevant to weight loss and obesity control. 32 Thus, comparing two biologically active interventions (soy and milk) could mask, an otherwise, a more marked effect of soy. In addition, the increase in protein and energy intake due to supplementation may have overshadowed a greater treatment effect. The effect size may be related to treatment duration. Although this study was of relatively long duration when compared with other soy trials, a longer study may yield a more notable treatment effect. In studies on hormone treatment (HT) and body composition, the duration of estrogen use was often several years. [33] [34] [35] In the FELS study, 36 women who had used estrogen therapy for 45 years had significantly higher fat free mass than the non-users, whereas little change was observed in studies of shorter duration. The mechanisms whereby soy protein and isoflavones exert its effects on body mass and adipose tissue are not clearly understood. Except for estrogen-like activity, 37 isoflavones may inhibit adipose tissue accumulation and regulate adipogenic differentiation through numerous other pathways such as PPARs and SREBPs, 37 or acting as a tyrosine kinase inhibitor. 38 The capacity of soy protein to regulate weight and lipid metabolism might be related to its amino acid constitution. Soy peptide may improve the thermic response of brown adipose tissue, promote satiation, and alter secretion of gut hormones. 39 Our study has several limitations. First, the use of bioelectrical impedance method for body composition measures had advantages but also limitations. Body fat should ideally be measured by the gold standards, underwater weighing, or dual x-ray absorptiometry, but these two methods are generally impractical and expensive. Bioelectrical impedance analysis (BIA) is a practical and good alternative 40, 41 with established validity and reliability in the assessment of body composition. [42] [43] [44] The use of built-in software to assess BF% with weight, height, age, and sex as additional parameters improved the accuracy of body composition measurement and with a precision error similar to dual x-ray absorptiometry and underwater weighing. 45 The BIA instrument used in our study has limitation in differentiating regional fat from total FM. Further studies of soy effect on abdominal fat change are required. Another limitation is that equol production status has not been assessed in our trial. Evidence has suggested that the clinical efficacy of isoflavones in humans depends on their ability to produce equol, a microbial metabolite of daidzein and is more estrogenic than daidzein. 46, 47 As only 30-50% of the Chinese population can produce equol after soyfood ingestion, equol-producing status may be an important modifier of the effects of isoflavones. Compared with the earlier studies, this study has a relatively large sample. Subjects' compliance was good with only 7.8% attrition rate. The study also had successful blinding efficacy. Three supplements were formulated into iso-caloric powder with similar nutrient profile allowing the comparison of supplementation effects only between protein variety (soy or milk) and isoflavone content (with or without). Furthermore, dietary intake and physical activity, the two most important modifiers of treatment effect, were monitored and were found similar across the whole intervention period. This double-blind randomized placebo-controlled trial revealed that 6-month daily supplementation with 15 g soy protein and 100 mg isoflavones resulted in a mild but significant BW and fat reduction among postmenopausal Chinese women. However, longer-term trials are warranted to investigate the potential effects of soy, the appropriate dosages, and the responsible components on improvement of body composition among overweight and obese populations.
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